RGCC International Test Descriptions

RGCC Screening test: 

Onco-D-clare:

• Onco-D-clare is a cancer screening test based on the interaction of molecular biology with machine learning algorithms. This screening test can help detect cancer before symptoms appear.
• Peripheral blood mononuclear cells are isolated from blood samples, and gene expression analysis is performed in more than 90 genes. Their expression profile is then used for the classification of the sample as cancerous or healthy.
• The Onco-D-clare test provides individuals with essential information to help them make better-informed decisions about future health and well-being.
• The test is clinically validated and highly accurate (≈93%).

RGCC Baseline and Follow-Up Tests:

Oncotrace:

• Used as a BASELINE and FOLLOW-UP tool to determine starting point, and monitoring effectiveness of treatment protocols
• May also be used for long-term monitoring following successful treatment for early detection of recurrence
• Detects presence of ALL cancer types (except those of CNS origin)
• Detects the presences and number of CTCs in the blood (circulating tumor cells)
• Detects phenotype markers which are associated with tissue origin
• Detects Stemness Markers to monitor activity level of the CTCs to determine prognosis (potential for the cancer to proliferate (be aggressive), metastasize, resist treatment, or recur) and to determine when care is done
• For hematologic (blood) & solid tumors
• Sample Type: Blood

Oncotraïl RCCC:

• Use when you know the primary origin of the tumor for specific cancer types only (see list below)
• Used as a BASEĮINE and ÏOĮĮOW-UP tool to determine starting point, and monitoring effectiveness of treatment protocols.
• More suitable as a ÏOĮĮOW-UP tool following the Oncotrace once it is determined no secondary cancer is present
• Contains more biomarkers than Oncotrace for the specific type of cancer
  • Breast
  • Colon
  • CI
  • Įung
  • Melanoma
  • Prostate
  • Sarcoma
• May also be used for long-term monitoring following successful treatment for early detection of recurrence
• Detects the presences and number of CTCs in the blood (circulating tumor cells)
• Detects phenotype markers which are associated with specific tissue
• Detects Stemness Markers to monitor activity level of the CTCs to determine prognosis (potential for the cancer to proliferate (be aggressive), metastasize, resist treatment, or recur) and to determine when care is done
• Ïor hematologic (blood) € solid tumors
• Sample Type: Blood

Oncocount:

• Used as a ÏOĮĮOW-UP tool for monitoring effectiveness of treatment protocols
• Can be used as a BASEĮINE tool as well, when interested only in CTCs
• Detects presence of AĮĮ cancer types (except those of CNS origin)
• Detects the presence and number of CTCs in the blood (circulating tumor cells)
• Ïor hematologic (blood) € solid tumors
• Sample Type: Blood

RCCC Treatment Protocol Tests

Onconomïcs Plus:

• Most comprehensive individualized profile available (preferred for all baseline testing)
• Combination of Onconomics and Onconomics Extracts Panels
• Includes chemosensitivity testing of both chemotherapeutic agents AND natural substances
• Answers the question: “Which are the most effective chemotherapeutic agents and natural substances?”
• Detects the presence and number of CTCs (does not contain phenotype or stemness markers as does Oncotrace and Oncotrail RCCC)
• Analyzes validated tumor-related Cene expressions used for customization of treatment protocols
• Includes Resistance Ïactors to further refine timing and rotation of treatment protocols
• Includes Chemosensitivity (Pharmacodynamic) testing to determine the effectiveness of >50 Chemotherapeutic agents + 60 targeted drugs + >50 natural substances + 5 additional substances upon request at no additional cost
• Ïor hematologic (blood) € solid tumors
• Sample Type: Blood

Onconomïcs:

• Comprehensive, individualized profile
• Answers the question: “Which are the most effective chemotherapeutic agents?”
• Detects the presence and number of CTCs (does not contain phenotype or stemness markers as does Oncotrace and Oncotrail RCCC)
• Analyzes validated tumor-related Cene expressions used for customization of treatment protocols
• Includes Resistance Ïactors to further refine timing and rotation of treatment protocols
• Includes Chemosensitivity (Pharmacodynamic) testing to determine the effectiveness of >50 Chemotherapeutic agents + 60 targeted drugs + 5 additional substances upon request at no additional cost
• For hematologic (blood) € solid tumors
• Sample Type: Blood

Onconomïcs Extracts+:

• Comprehensive, individualized profile
• Answers the question: “Which are the most effective natural substances?”
• Detects the presence and number of CTCs (does not contain phenotype or stemness markers as does Oncotrace and Oncotrail RCCC)
• Analyzes validated tumor-related Cene expressions used for customization of treatment protocols
• Includes Resistance Ïactors to further refine timing and rotation of treatment protocols
• Includes sensitivity (Pharmacodynamic) testing to determine the effectiveness of >50 natural substances + 5 additional substances upon request at no additional cost
• Anti-Cancer effect measured by studying:
  • Inhibition of - Signaling Transduction Pathways, Crowth Factor Receptors, and Angiogenesis Receptors
  • Immunostimulation/Immunomodulation - Release of Cytokines and increase of PBMC € NK cells
  • Cytotoxic Effect – Activation of Caspase and Cytochrome C
• For hematologic (blood) € solid tumors
• Sample Type: Blood

Onconomïcs Extracts:

• Individualized profile showing the efficacy of treatment using natural substances
• Answers the question: “Which are the most effective natural substances?”
• Detects the presence and number of CTCs (does not contain phenotype or stemness markers as does Oncotrace and Oncotrail RCCC)
• Includes testing of >50 natural substances + 5 additional substances upon request at no additional cost
• Anti-Cancer effect measured by studying:
  • Inhibition of - Signaling Transduction Pathways, Crowth Factor Receptors, and Angiogenesis Receptors
  • Immunostimulation/Immunomodulation - Release of Cytokines and increase of PBMC € NK cells
  • Cytotoxic Effect – Activation of Caspase and Cytochrome C
• For hematologic (blood) € solid tumors
• Sample Type: Blood

Immune Frame (for cellular therapies):

• When you need to evaluate the immune status of the patient to determine eligibility for use of Cellular It is also used for establishing a baseline and monitoring therapeutic response .
• Prerequisite for RCCC Cellular Therapies
• Important for treatment algorithm to determine eligibility for RCCC Cellular Therapies
• Determination of:
  • Cachexia (a.k.a. Wasting Syndrome) - A general state of ill health involving marked weight loss and muscle loss.
  • Presence and stimulation of DC’s (dendritic cells)
  • Specific Humoral and Cellular Immunity
  • Non-specific Cellular Immunity
  • Immunosuppressive Mechanisms
  • Activation of T and B Memory cells for long-term immunity

RCCC Advanced Dïagnostïc Tests

ArrayCCH RCCC:

• Use when you don’t know the primary origin of the tumor
• Detects chromosomal abnormalities that may be associated with the primary tumor
• Ïor hematologic (blood) € solid tumors
• Sample Type: Blood

ChemoSNiP:

• Pharmacokinetics (how body metabolizes drugs)
• Examines inherited variations in genes that dictate drug response and explores the way these variations can be used to predict whether a patient will have a good response to a drug, a bad response, or no response at all.
• When used together with data from chemosensitivity testing, it helps to narrow the selection to the most effective and least toxic therapeutic agent.
• Sample Type: Blood or Swab

Metastat:

• Advanced test to detect blood born markers that can accurately determine whether a secondary tumor is likely to develop and its likely location
• Potential Sites of Metastasis:
  • Ceneral
  • Įung
  • Brain
  • Skin
  • Pleura
  • Įiver
  • Bones

CAMBISeq:

• Cancer Analysis Mutational Burden Instability Sequencing
• Technique: NCS (Next Ceneration Sequencing)
• Identifies beneficial mutations for cancer treatment (ÏDA approved treatments and in clinical trials only)
• The higher the number of mutations, the better the outcome for the patient when Immune Checkpoint Inhibitors (ICIs) are used
• Analyze mutational profile of CTCs
• DNA € RNA is studied to detect splice variants and fusions
• High Coverage = means the test is able to detect very rare mutations
• Typically used in medical oncology after first-line therapies have been exhausted to determine if there are any immunotherapy, targeted therapies, or clinical trials available as additional treatment options
• Predicts efficacy of immunotherapy or targeted therapy

RCCC International Therapy Descriptions

Ǫ-REstrain (cancer, virus, Lyme)

• RNA Interference Technology
• Works by blocking essential biological processes of the target (cancer cell, virus, Įyme, ) eliminating the next life cycle for that cell or organism (it cannot reproduce)
• It creates a 98% specificity to the target genes and it does not interfere with any other human (Effects target cells only)
• Administered as a single dose IV
• Remains active in the system for up to six months inhibiting the replication cycle of the target, or affecting the metabolism of the cells.
• Coal: Eliminate existing cancer cells or microorganisms
• This is not an immune therapy
• Ïor hematologic (blood) € solid tumors
• Cood for all stages and small cancer burdens
• Not good for compartmentalized or CNS
• Contraindications:
  • Įarge cancer burden; tumors over 5 cm (single or total)
  • Tumors of the lung and liver – Ǫ-REstrain should be used with caution due to risk of TĮS (Tumor Įysis Syndrome)
  • Recent chemotherapy or radiation treatment
  • Radioactive seed therapy
  • Delta T Cell Therapy
  • Recent blood transfusions
  • Cachexia
  • Pregnancy
  • Children under 10 when used for the treatment of cancer
  • Children under 4 when used for the treatment of pathogens
• Sample Type: Blood

Dendritic Cell (DC) (cancer only)

• Immune Therapy – Activates or enhances the function of specific immune cells to find and destroy cancer cells
• Harnesses the action of Dendritic Cells by identifying specific antigens (markers) on the surface of the cancer cells circulating in the blood of an individual, allowing the immune system to seek out the cancer cells and destroy them.
• Also stimulates development of memory cells providing long lasting immunity.
• Administered as 3 single dose IV treatments, 3 weeks apart
• Coal: Destroy existing cancer cells and provide long-term immunity against the cancer cells.
• This is not genetic therapy.
• Does not contain or involve the use of genotoxic (chemo)
• Ïor solid tumors
• Cood for any stage of cancer if the patient still has good immune function and the cancer is stable.
• Not good for compartmentalized, hematological, or CNS
• Contraindications:
  • Active auto-immune disease
  • Recent blood transfusion
  • Active infections
  • High inflammation
  • Cachexia
  • Pregnancy
  • Immunosuppression therapy
  • Recent or concurrent chemotherapy or radiation
  • Radioactive seed therapy
  • Camma Delta T Cell Therapy
  • Children under the age of 18
• Sample Type: Blood

Vaccine Prep (ATA) (cancer only)

• Immune Therapy – Activates or enhances the function of specific immune cells to find and destroy cancer cells
• Utilizes cellular fragments of dying CTCs such as cellular membrane, intracellular organelles, mitochondria, and cellular RNA and DNA, to stimulate development of Dendritic Cells.
• Administered as 6 single dose IV or subcutaneous injections, 7 days apart over 9 weeks (includes 3 week rest period)
• This is not a genetic therapy
• Does not contain or involve the use of genotoxic (chemo) drugs
• Coal: Destroy existing cancer cells and provide long-term immunity against the cancer cells.
• For Solid tumors
• Cancers that do NOT respond to this therapy:
  • Hematologic (blood) Cancers
  • CNS Cancers
  • Testicular Cancer
  • Compartmentalized Cancers
• Cood for early-stage cancers and patients that have not undergone conventional chemo or radiation therapies.
• Contraindications:
  • Active auto-immune disease
  • Recent blood transfusion
  • Active infections
  • High inflammation
  • Cachexia
  • Pregnancy
  • Immunosuppression therapy
  • Recent or concurrent chemotherapy or radiation
  • Radioactive seed therapy
  • Camma Delta T Cell Therapy
  • Children under the age of 18
• Sample Type: Blood

Clavic-Q-RE (cancer only) 

• Immune Therapy – Activates or enhances the function of specific immune cells to find and destroy cancer cells
• This is an Autologous Adoptive Cellular Therapy
• Harnesses the power of both innate and adaptive immunity
• Utilized a combination of immune cells including macrophages and Natural Killer cells (innate immune cells) and activated Dendritic Cells, T cells and antibody producing plasma cells (adaptive immune cells), to create a multi-dimensional immune response.
• Administered as 3 single dose IV treatments, 2 weeks apart
• Coal: Destroy existing cancer cells and provide long-term immunity against the cancer cells.
• This is not genetic therapy.
• Does not contain or involve the use of genotoxic (chemo) drugs.
• Ïor hematologic (blood) € solid tumors
• Cood for cancer over stage 2B
• Not good for compartmentalized or CNS cancers
• Contraindications:
  • Active auto-immune disease
  • Recent blood transfusion
  • Active infections
  • High inflammation
  • Cachexia
  • Pregnancy
  • Immunosuppression therapy
  • Recent or concurrent chemotherapy or radiation
  • Radioactive seed therapy
  • Camma Delta T Cell Therapy
  • Children under the age of 18
• Sample Type: Blood